ArticleBriefings in bioinformatics2020
Clinical trials, progression-speed differentiating features and swiftness rule of the innovative targets of first-in-class drugs.
Article in Briefings in bioinformatics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed.
- hERG-MFFGNN: An Explainable Deep Learning Model for Predicting Cardiotoxicity Using Multi-feature Fusion and Graph Neural Networks.Interdisciplinary sciences, computational life sciences · 2026Article
- DDID: a comprehensive resource for visualization and analysis of diet-drug interactions.Briefings in bioinformatics · 2024Article
- FERREG: ferroptosis-based regulation of disease occurrence, progression and therapeutic response.Briefings in bioinformatics · 2024Article
- VARIDT 3.0: the phenotypic and regulatory variability of drug transporter.Nucleic acids research · 2024Article
- ADCdb: the database of antibody-drug conjugates.Nucleic acids research · 2024Article
- TTD: Therapeutic Target Database describing target druggability information.Nucleic acids research · 2024Article
- TheMarker: a comprehensive database of therapeutic biomarkers.Nucleic acids research · 2024Article
- RNAenrich: a web server for non-coding RNA enrichment.Bioinformatics (Oxford, England) · 2023Article
- ANPELA: Significantly Enhanced Quantification Tool for Cytometry-Based Single-Cell Proteomics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Whale optimization with random contraction and Rosenbrock method for COVID-19 disease prediction.Biomedical signal processing and control · 2023Article
- CovInter: interaction data between coronavirus RNAs and host proteins.Nucleic acids research · 2023Article
- DrugMAP: molecular atlas and pharma-information of all drugs.Nucleic acids research · 2023Article
- DRESIS: the first comprehensive landscape of drug resistance information.Nucleic acids research · 2023Article
- M6AREG: m6A-centered regulation of disease development and drug response.Nucleic acids research · 2023Article
- Uncovering the dynamic effects of DEX treatment on lung cancer by integrating bioinformatic inference and multiscale modeling of scRNA-seq and proteomics data.Computers in biology and medicine · 2022Article
- Mutational Slime Mould Algorithm for Gene Selection.Biomedicines · 2022Article
- Insights into the structural peculiarities of the N-terminal and receptor binding domains of the spike protein from the SARS-CoV-2 Omicron variant.Computers in biology and medicine · 2022Article
- Investigating the structure-activity relationship of marine polycyclic batzelladine alkaloids as promising inhibitors for SARS-CoV-2 main protease (MComputers in biology and medicine · 2022Article
- Structural basis of Omicron immune evasion: A comparative computational study.Computers in biology and medicine · 2022Article
- Multilevel threshold image segmentation for COVID-19 chest radiography: A framework using horizontal and vertical multiverse optimization.Computers in biology and medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drugs produce their therapeutic effects by modulating specific targets, and there are 89 innovative targets of first-in-class drugs approved in 2004-17, each with information about drug clinical trial dated back to 1984. Analysis of the clinical trial timelines of these targets may reveal the trial-speed differentiating features for facilitating target assessment. Here we present a comprehensive analysis of all these 89 targets, following the earlier studies for prospective prediction of clinical success of the targets of clinical trial drugs. Our analysis confirmed the literature-reported common druggability characteristics for clinical success of these innovative targets, exposed trial-speed differentiating features associated to the on-target and off-target collateral effects in humans and further revealed a simple rule for identifying the speedy human targets through clinical trials (from the earliest phase I to the 1st drug approval within 8 years). This simple rule correctly identified 75.0% of the 28 speedy human targets and only unexpectedly misclassified 13.2% of 53 non-speedy human targets. Certain extraordinary circumstances were also discovered to likely contribute to the misclassification of some human targets by this simple rule. Investigation and knowledge of trial-speed differentiating features enable prioritized drug discovery and development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.